Dapagliflozin/metformin - AstraZeneca
Alternative Names: Dapagliflozin/metformin FDC; Dapagliflozin/metformin XR; Ebymect; Metformin/dapagliflozin; Oxramet; Xigduo XR; Xigduo XR FDCLatest Information Update: 28 Jun 2023
Price :
$50 *
At a glance
- Originator Bristol-Myers Squibb
- Developer AstraZeneca
- Class Antihyperglycaemics; Biguanides; Chlorobenzenes; Glucosides; Pyrans; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 27 Jun 2023 Registered for Type 2 diabetes mellitus (In volunteers, In adults) in China (PO)
- 14 Jun 2021 AstraZeneca completes a phase-I clinical trials in Type 2 diabetes mellitus (In adults, In volunteers) in China (PO, Tablet) (NCT04856007)
- 12 Apr 2021 Phase-I clinical trials in Type 2 diabetes mellitus (In adults, In volunteers) in China (PO, Tablet) (NCT04856007)